QuidelOrtho Corporation
NASDAQ:QDELMedical - Instruments & Supplies
+$0.09 today
- Market cap
- $656.62M
- Beta
- 0.76
- P/E (TTM)
- -0.7
- EPS (TTM)
- -$17.76
Volume 2.13M
Average 2.35M
QDEL Total Current Assets
All assets expected to be converted to cash or used up within one year.
QuidelOrtho CorporationNASDAQ: QDEL
Total Current Assets · Q1 FY2026 · quarter ended Mar 2026
Total current assets rises 9.4% from a year ago
Total current assets stood at $1.38B at the end of Q1 FY2026, up 9.4% from a year earlier and down 4.9% from the prior quarter. Over 3 fiscal years it compounded at -2.8% a year.
Context
- Total current assets amounted to 24.5% of total assets at the end of Q1 FY2026, up 5.0 pp from a year earlier.
- Total current assets increased in 1 of the last 3 fiscal years.
What to watch
Whether total current assets keeps rising in the next quarterly balance sheet after a +9.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Assets history
USD · from the balance sheet
- Latest · FY2025
- 1.45B USD
- Year-over-year change
- +18.7%
- 4-year CAGR
- +0.1%
| Period | Period end | Total Current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-28 | 1.45B | +18.7% |
| FY2024 | 2024-12-29 | 1.22B | -7.0% |
| FY2023 | 2023-12-31 | 1.31B | -16.8% |
| FY2022 | 2023-01-01 | 1.58B | +9.4% |
| FY2021 | 2021-12-31 | 1.44B | — |
Total Current Assets vs competitors
How QDEL compares with its peers on the latest reported figures
- QDEL's Mar 2026 total current assets of $1.38B is the 5th highest of the 9 companies compared; the peer median is $1.42B.
- Its year-over-year change of +9.4% is the 4th highest of 9, against a peer median of +5.1%.
- Total current assets amounts to 24.5% of total assets for QDEL, versus a peer median of 29.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $25.62B | +14.9% | +4.4% | 22.4% | |
| Sep 2026 | $3.12B | +29.5% | +7.8% | 18.1% | |
| Jun 2026 | $3.02B | +7.4% | -2.7% | 29.5% | |
| Jul 2026 | $2.3B | +2.8% | -12.0% | 19.1% | |
| Mar 2026 | $1.38B | +9.4% | -2.8% | 24.5% | |
| Mar 2026 | $535.36M | -27.4% | +13.8% | 28.8% | |
| Mar 2026 | $240.78M | -23.3% | -7.0% | 63.5% | |
| Dec 2025 | $35.9M | -12.7% | -8.4% | 34.1% | |
NNNNAnbio Biotechnology Class A Ordinary Shares | Dec 2025 | $30.24M | +63.2% | +29.4% | 100.0% |
| Peer median (excluding QDEL) | $1.42B | +5.1% | +0.8% | 29.1% | |
Competitors are the stored peer set for QDEL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Jan 2023 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 802.8M | 292.9M | 118.9M | 98.3M | 169.8M |
| Short-term Investments | 25.7M | 52.1M | 48.4M | 0 | 32.4M |
| Net Receivables | 393.8M | 586.4M | 488.4M | 451.3M | 417M |
| Inventory | 198.8M | 524.1M | 577.8M | 533.7M | 577.6M |
| Other Current Assets | 4.6M | 22.9M | 10M | 58.3M | 0 |
| Total Current Assets | 1.44B | 1.58B | 1.31B | 1.22B | 1.45B |
| Property, Plant & Equipment (Net) | 476.8M | 1.52B | 1.61B | 1.55B | 1.51B |
| Goodwill | 337M | 2.48B | 2.49B | 649.5M | 0 |
| Intangible Assets | 98.7M | 3.12B | 2.93B | 2.74B | 2.56B |
| Long-term Investments | 37.9M | 21M | 7.4M | 21.7M | 0 |
| Tax Assets | 20.1M | 16.4M | 25.9M | 0 | 0 |
| Other Non-current Assets | 19.6M | 122.7M | 179.6M | 249M | 244.4M |
| Total Non-current Assets | 990.1M | 7.28B | 7.25B | 5.2B | 4.32B |
| Total Assets | 2.43B | 8.86B | 8.56B | 6.42B | 5.77B |
| Account Payables | 101.5M | 283.3M | 294.8M | 246M | 279.4M |
| Short-term Debt | 300K | 207.5M | 139.8M | 341.8M | 178.3M |
| Tax Payables | 77.1M | 51.6M | 29M | 5.4M | 11.5M |
| Deferred Revenue | 1.9M | 76.4M | 36.8M | 33.5M | 37.8M |
| Other Current Liabilities | 65.5M | 156.4M | 127.8M | 96.8M | 164.3M |
| Total Current Liabilities | 323.5M | 1.01B | 833.8M | 998.8M | 966.1M |
| Long-term Debt | 400K | 2.43B | 2.27B | 2.14B | 2.47B |
| Deferred Tax Liabilities | 0 | 213.2M | 192.2M | 76.5M | 90M |
| Deferred Revenue (Non-current) | 0 | 9.4M | 0 | 17.3M | 0 |
| Other Non-current Liabilities | 48.5M | 74.4M | 83.6M | 38M | 166.4M |
| Total Non-current Liabilities | 177.5M | 2.91B | 2.72B | 2.44B | 2.88B |
| Total Liabilities | 501M | 3.92B | 3.56B | 3.44B | 3.85B |
| Common Stock | 0 | 0 | 100K | 100K | 100K |
| Retained Earnings | 1.65B | 2.2B | 2.19B | 135.8M | (996M) |
| Accumulated OCI | 400K | (67.6M) | (30M) | (36.2M) | (15.4M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 1.93B | 4.93B | 5.01B | 2.98B | 1.92B |
| Total Debt | 139.3M | 2.85B | 2.61B | 2.68B | 2.83B |
| Net Debt | (663.5M) | 2.56B | 2.5B | 2.58B | 2.66B |
QuidelOrtho Corporation
NASDAQ:QDEL
Intrinsic Alpha fair value
Locked
Current Price
$9.57
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.